Nuvectis Pharma, Inc.

NVCT Healthcare Biotechnology

In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

18.48 0.45 −2.38%
Market cap
$618.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(158.88%) (205.30%) (168.24%) (233.30%)
ROA
(105.13%) (114.76%) (106.54%) (122.61%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(115.81%) (156.80%) (208.08%) (333.35%)
Free Cash Flow per Share
(0.64) (0.73) (0.78) (0.83)
Free Cash Flow
(14.50) (16.01) (18.35) (19.51)
Other line items

Show all line items

Columns are period end dates